Is gemcitabine cost effective in cancer treatment?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 3, 2007, Pages 239-249

  Toschi, Luca ^a   Finocchiaro, Giovanna ^a   Ceresoli, Giovanni Luca ^a   Zucali, Paolo Andrea ^a   Cavina, Raffaele ^a   Garassino, Isabella ^a   De Vincenzo, Fabio ^a   Santoro, Armando ^a   Cappuzzo, Federico ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Chemotherapy; Gemcitabine non small cell lung cancer; Pharmacoeconomics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DEOXYCYTIDINE KINASE; DOCETAXEL; DOXORUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GROWTH FACTOR; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; DRUG WITHDRAWAL; EDEMA; FEVER; FLU LIKE SYNDROME; HEALTH CARE COST; HOSPITAL COST; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHARMACOGENETICS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 34547602958     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.3.239     Document Type: Article

References (78)

1. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J Clin. Oncol. 17(11), 3522-3530 (1999).
2. Cardenal F, Lopez-Cabrerizo MP, Anton A et al Randomized Phase III study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 17(1), 12-18 (1999).
3. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
4. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006).
5. Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel vs. paclitaxel as frontline therapy for metastatic breast cancer: first report of overall survival. Proc. Am. Soc. Clin. Oncol. 23(5), A510 (2004).
6. Von der Maase H, Hansen SW et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
7. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre. extended Phase II study. Eur. J. Cancer 32A(2), 243-248 (1996).
8. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. 12(8), 1535-1540 (1994).
9. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Oncol. 24(2 Suppl.7), S750-S755 (1997).
10. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br. J. Cancer 83(4), 447-453 (2000).
11. Lees M, Aristides M. Maniadakis N, McKendrick J, Botwood N, Stephenson D. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 20(5), 325-337 (2002).
12. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 57(1), 20-28 (2002).
13. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau. L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J. Natl Cancer. Inst. 92(16), 1321-1329 (2000).
14. Manegold C, Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised Phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. 8(6), 525-529 (1997).
15. Perng RP, Chen Ym, Ming-Liu J et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a Phase 11 randomized study. J. Clin. Oncol. 15(5), 2097-2102 (1997).
16. Vansteenkiste JF, Vandebroek JE, Nackaerts KL et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised Phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann. Oncol. 12(9), 1221-1230 (2001).
17. Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur. Respir. J. 27 (5), 895-901 (2006).
18. Koch P, Johnson N, van Schaik J et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs 6(Suppl. 6), 49-54 (1995).
19. Copley-Merriman C, Corral J, King K et al. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer 14(1), 45-61 (1996).
20. Copley-Merriman C, Martin C, Johnson N, Sacristan JA, Drings PA, Bosanquet N. Economic value of gemcitabine in non-small cell lung cancer. Semin. Oncol. 23(5 Suppl. 10), 90-98 (1996).
21. Tennvall GR, Fernberg JO. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in Stage IIIB and IV non-small cell lung cancer. Med. Oncol. 15(2), 129-136 (1998).
22. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18(1), 122-130 (2000).
23. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
24. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
25. Comella P, Frasci G, Panza N et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J. Clin. Oncol. 18(7), 1451-1457 (2000).
26. Schiller J, Tilden D, Aristides M et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43(1), 101-112 (2004).
27. Novello S, Kielhorn A, Stynes G et al. Italian Lung Cancer Project Investigators. Cost-minimisation analysis comparing gemcitabine/ cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 48(3), 379-387 (2005).
28. Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two Phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 52(3), 365-371 (2006).
29. Martoni A, Marino A, Sperandi F et al. Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur. J. Cancer 41(1), 81-92 (2005).
30. Gebbia V, Galetta D, Caruso et al. Phase III trial comparing cisplatin (CDDP) plus weekly vinorelbine (VNR) and CDDP plus 1+8 schedule in advanced non small cell lung cancer (NSCLC). Lung Cancer 41(Suppl. 2), 63 (2003) (Abstract O216).
31. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-smallcell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(16), 3025-3034 (2003).
32. Cappuzzo F, Novello S, De Marinis F et al. A randomized Phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinumbased chemotherapy. Lung Cancer 52(3), 319-325 (2006).
33. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357(9267), 1478-1484 (2001).
34. Chen YM, Perng RP, Lee YC et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable nonsmall- cell lung cancer previously untreated. Ann. Oncol. 13(1), 108-115 (2002).
35. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. 20(17), 3578-3585 (2002).
36. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J. Clin. Oncol. 21(21), 3909-3917 (2003).
37. Neymark N, Lianes P, Smit EF, van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 23(11), 1155-1166 (2005).
38. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 7(6), 593-600 (1996).
39. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. 81(6), 882-885 (1994).
40. Heinemann V, Hinke A, Boeck S, Louvet C. Benefit from gemcitabine-based combination treatment in advanced pancreatic cancer: A meta-analysis of randomized trials. ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 129).
41. Ragnarson-Tennvall G, Wilking N. Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care. Pharmacoeconomics 15(4), 377-384 (1999).
42. Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur. J. Health Econ. 4(3), 216-221 (2003).
43. Trippoli S, Messori A. Cost-effectiveness of gemcitabine as first-line therapy for patients with advanced pancreatic cancer. Value Health 2, 22 (1999).
44. Ward S, Morris E, Bansback N et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol. Assess. 5(24), 1-70 (2001).
45. Ishii H, Furuse J, Kinoshita T et al. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn. J. Clin. Oncol. 35(9), 526-530 (2005).
46. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. 23(Suppl. 1) (2005) (Abstract 1).
47. Grubbs SS, Grusenmeyer PA, Petrelli NJ, Gralla RJ. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? Proc. Am. Soc. Clin. Oncol. 24, S18, (2006) (Abstract 6048).
48. Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 211-218 (2007).
49. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 6(Suppl. 6), 61-62 (1995).
50. Friedlander M, Millward MJ, Bell D et al. A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9(12), 1343-1345 (1998).
51. Prasad M, Ben-Porat L, Hoppe B et al. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecol. Oncol. 93(1), 223-228 (2004).
52. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a Phase II trial with gemcitabine. J. Clin. Oncol. 13(11), 2731-2736 (1995).
53. Possinger K, Kaufmann M, Coleman R et al. Phase II study of gemcitabine as firstline chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2), 155-162 (1999).
54. Valerio MR, Cicero G, Armata MG et al. Gemcitabine(G) in pretreated breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 20(51B) (2001) (Abstract 1953).
55. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a Phase II trial. Oncology 62(1), 2-8 (2002).
56. Spielmann M, Llombart-Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60(4), 303-307 (2001).
57. Brodowicz T, Kostler WJ, Moslinger R et al. Single-agent gemcitabine as secondand third-line treatment in metastatic breast cancer. Breast 9(6), 338-342 (2000).
58. Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs. 10(7), 625-631 (1999).
59. Gerson R, Serrano OA, Villalobos A, Ortiz C, Sánchez-Forgach E. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc. Am. Soc. Clin. Oncol. 19 (2000) (Abstract 572).
60. Modi S, Currie VE, Seidman AD et al. A Phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin. Breast Cancer 6(1), 55-60 (2005).
61. Rha SY, Moon YH, Jeung HC et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res. Treat. 90(3), 215-221 (2005).
62. Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts) results of a European Phase III study. Proc. Am. Soc. Clin. Oncol. 23(S24) (2005) (Abstract 581).
63. Jones J, Takeda A, Tan SC et al. Gemcitabine for metastatic breast cancer. Health Technol. Assess. 11(19), 1-81 (2006).
64. Silberman G, Gupta S, Berkowitz N, Leyland-Jones B. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1629).
65. Le Lay K, Payet S, Riou-Franca L, Chemali N, Launois R. A cost-utility analysis of first line chemotherapy regimens in the treatment of metastatic breast cancer after anthracyclines failure. ISPOR 8th Annual Congress. Palazzo Degli Affari, Florence, Italy (2005) (Abstract 5196).
66. Eniu A, Carlson RW, Aziz Z et al. Global Summit Treatment and Allocation of Resources Panel. Breast cancer in limitedresource countries: treatment and allocation of resources. Breast J. 12(Suppl. 1), S38-S53 (2006).
67. Loehrer PJ Sr, Elson P, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colonystimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 12(3), 483-488 (1994).
68. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15(7), 2564-2569 (1997).
69. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8(6), 1050-1055 (1990).
70. Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit. Rev. Oncol. Hematol. 47(2), 171-179 (2003).
71. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4731-4737 (2006).
72. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10(4), 1318-1325 (2004).
73. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17(12), 1818-1825 (2006).
74. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120(6), 1355-1363 (2007).
75. Kwon WS, Rha SY, Choi YH et al. Ribonucleotide reductase M1 ( RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 16(6), 429-438 (2006).
76. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95(9), 753-757 (2004).
77. Marce S, Molina-Arcas M, Villamor N et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91(7), 895-902 (2006).
78. Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66(7), 3928-3935 (2006).